- 1. SNM 2012 Image of the Year: Bi-213-DOTATOC for a New Treatment for GEP-NET Tumors Resistant to Standard Therapies:
- (In the News)
- Miami Beach, Fla. – The Society of Nuclear Medicine's (SNM) 2012 Image of the Year illustrates the effectiveness of Bi-213-DOTATOC for the peptide receptor alpha-therapy of gastroenteropancreatic neuroendocrine ...
- Created on 20 June 2012
- 2. Lutathera Approved in the US
- (News)
- ... (FDA) has approved the new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), ...
- Created on 27 June 2018
- 3. 2014 SNMMI Patient Education Day
- (News)
- For the second year in a row, NorCal CarciNET Community and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a patient education day during the SNMMI's Annual Meeting. The program took ...
- Created on 18 August 2014
- 4. Updates from the Ga68 Working Group
- (News)
- ... trials. In October 2013, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) received orphan drug designation for Ga-68 DOTATOC. Click hereto see the slides from the Gallium Information Session ...
- Created on 18 August 2014
- 5. Ga68 - Orphan Drug Announcement
- (In the News)
- BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine ...
- Created on 20 November 2013
- 6. PRRT Multi-Center Trial Now Open
- (In the News)
- A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1) is now open ...
- Created on 21 July 2013
- 7. Pre Second World GA68 Congress Publication
- (Conferences)
- ... Original Articles Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience Bhagwant Rai Mittal, Kanhaiyalal Agrawal, Jaya Shukla, Anish Bhattacharya, Baljinder Singh, Ashwani ...
- Created on 11 February 2013
- 8. PET imaging could lead to better care for neuroendocrine cancer
- (In the News)
- ... the Society of Nuclear Medicine's 59th Annual Meeting. Results of the study indicated that PET/CT and Ga-68 DOTATATE was highly sensitive and specific for assessing neuroendocrine tumors and changed ...
- Created on 14 June 2012
- 9. Multicenter PRRT Clinical Trial Announced
- (In the News)
- ... parallel-group phase III study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide ...
- Created on 20 April 2012
- 10. Susan's Stor
- (Bad Berka)
- ... more in one week about my carcinoid than we had in the previous 10 years. This was mostly due to the Gallium-68 DOTATOC PET/CT Scan and Dr. Baum's experience in treating over 1,000 patients. The scan ...
- Created on 28 January 2012
- 11. CCAN NET Cancer Patients Conference Long Island
- (Past Conferences )
- CCAN's annual conference was held in Long Island, New York on August 20th 2011. The theme of the day long conference was "Multidisciplinary Approach to the Diagnosis Treatment and Monitoring of NETs." ...
- Created on 20 August 2011
- 12. Road to Basel - Terry Y.
- (Basel)
- ... days stay PRRT injection cost: 6000 CHF (Y90 DOTATOC) Total: 9240 CHF (CHF – Canton Helvetica Franc -- is the notation for Swiss currency. Switzerland is not a European Union country. Therefore, ...
- Created on 12 June 2011
- 13. Recently Published Articles
- (Publications)
- ... B, Baum RP, Reubi JC, Maecke HR. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem. 2011 Apr 28;54(8):2602-9. ...
- Created on 11 June 2011
- 14. JCO Article on PRRT shows significantly improved overall survival rates.
- (In the News)
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. Published in Journal of Clinical Oncology, ...
- Created on 27 May 2011
- 15. 1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy
- (In the News)
- 1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy THERANOSTICS – on the Way to Personalized Medicine Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin ...
- Created on 07 April 2011
- 16. Welcome to PRRTinfo.org
- (Uncategorised)
- ... to evolve since this site was first launched in May of 2011. in 2017/18 Lu177 Dotatate was approved in Europe and the United States. While one does not need to travel to Europe to receive PRRT, there are ...
- Created on 16 February 2011
- 17. Information for Referring Physicians
- (General MD)
- ... by OctreoScan or (preferable) by Ga-68 DOTATOC PET/CT. * Renal function and blood counts should be in the normal range. * Small bowel tumors (midgut), progressive under octreotide (Sandostatin, Somatuline) ...
- Created on 19 July 2010
- 18. What is PRRT?
- (PRRT)
- ... Lutetium-177 DOTATATE in 2013. 55916797 This type of molecular radiation therapy can only be conducted on patients who have somatostatin receptor-positive tumors. Many, but not all, forms of ...
- Created on 19 July 2010